FIELD: medicine.
SUBSTANCE: claimed is application of group of epothilone compounds, which have coefficient of average distribution between plasma and brain 0.3-1.5 in mice analysis by intravenous bolus injection, for obtaining medication for therapy of diseases of primary and secondary brain tumors. Epothilones efficiency with respect to xenotransplanted and intracranial human glioma is demonstrated.
EFFECT: compounds are distinguished not only by high anti-tumor activity with respect to brain tumor, but also by good penetration in brain tissues (areas under pharmacokinetic curves for blood plasma and for brain were similar in average).
10 cl, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITIONS WHICH CONTAIN EPOTHILONE, AND METHOD OF THEIR OBTAINING | 2005 |
|
RU2416407C2 |
| MODIFIED C-21-EPOTHILONES | 2000 |
|
RU2253652C2 |
| DERIVATIVES OF EPOTHILONE | 1998 |
|
RU2213741C2 |
| POLYMORPHIC MODIFICATIONS OF EPOTILONE ANALOG, METHODS FOR THEIR PREPARING, PHARMACEUTICAL COMPOSITIONS BASED ON THEREOF | 2001 |
|
RU2272039C2 |
| SYNERGIC METHODS AND COMPOSITIONS FOR CANCER TREATMENT | 2001 |
|
RU2264217C2 |
| EPOTHILONE DERIVATIVE FOR TREATMENT OF HEPATOME AND OTHER CANCER DISEASES | 2003 |
|
RU2358730C2 |
| SHIP1 MODULATORS AND METHODS RELATED THERETO | 2014 |
|
RU2679805C2 |
| TERPENOID DERIVATIVES AS USEFUL ANTITUMOR AGENTS | 1996 |
|
RU2179441C2 |
| METHOD FOR IDENTIFICATION OF ANTI-TUMOR TARGET ENZYMES | 2002 |
|
RU2319482C2 |
| USE OF MANNICH BASES BASED ON FUSIDIC ACID AS COMPOUNDS WITH ANTI-TUMOUR ACTIVITY | 2023 |
|
RU2819293C1 |
